Free Trial

Wall Street Zen Downgrades DENTSPLY SIRONA (NASDAQ:XRAY) to Hold

DENTSPLY SIRONA logo with Medical background

Wall Street Zen lowered shares of DENTSPLY SIRONA (NASDAQ:XRAY - Free Report) from a buy rating to a hold rating in a research report sent to investors on Saturday morning.

Several other analysts also recently weighed in on XRAY. Barrington Research raised their target price on DENTSPLY SIRONA from $20.00 to $21.00 and gave the company an "outperform" rating in a research note on Monday, May 12th. Piper Sandler lowered their price objective on DENTSPLY SIRONA from $20.00 to $16.00 and set a "neutral" rating for the company in a research note on Wednesday, April 30th. Needham & Company LLC reaffirmed a "hold" rating on shares of DENTSPLY SIRONA in a research report on Thursday, March 13th. Morgan Stanley downgraded shares of DENTSPLY SIRONA from an "overweight" rating to an "equal weight" rating and set a $14.00 price target for the company. in a research report on Tuesday, April 15th. Finally, Mizuho cut their price target on shares of DENTSPLY SIRONA from $21.00 to $18.00 and set a "neutral" rating on the stock in a report on Thursday, March 13th. Twelve research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $20.36.

Check Out Our Latest Research Report on DENTSPLY SIRONA

DENTSPLY SIRONA Stock Up 3.7%

NASDAQ:XRAY traded up $0.59 during mid-day trading on Friday, hitting $16.53. The company had a trading volume of 2,387,722 shares, compared to its average volume of 2,938,497. The business has a fifty day simple moving average of $15.79 and a 200-day simple moving average of $16.43. The firm has a market capitalization of $3.29 billion, a price-to-earnings ratio of -3.64, a PEG ratio of 1.14 and a beta of 0.94. DENTSPLY SIRONA has a 1 year low of $12.16 and a 1 year high of $27.95. The company has a current ratio of 1.10, a quick ratio of 0.76 and a debt-to-equity ratio of 0.79.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $0.43 EPS for the quarter, topping the consensus estimate of $0.29 by $0.14. The firm had revenue of $879.00 million for the quarter, compared to analyst estimates of $854.75 million. DENTSPLY SIRONA had a positive return on equity of 14.31% and a negative net margin of 24.42%. DENTSPLY SIRONA's revenue for the quarter was down 7.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.42 EPS. Equities analysts forecast that DENTSPLY SIRONA will post 1.84 earnings per share for the current fiscal year.

DENTSPLY SIRONA Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 11th. Stockholders of record on Friday, June 27th will be issued a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 3.87%. The ex-dividend date is Friday, June 27th. DENTSPLY SIRONA's dividend payout ratio (DPR) is presently -14.10%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in XRAY. Mirae Asset Global Investments Co. Ltd. acquired a new stake in DENTSPLY SIRONA in the first quarter worth $25,000. Colonial Trust Co SC acquired a new stake in shares of DENTSPLY SIRONA in the fourth quarter valued at approximately $26,000. Brooklyn Investment Group acquired a new stake in shares of DENTSPLY SIRONA in the first quarter valued at approximately $26,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of DENTSPLY SIRONA during the first quarter worth approximately $26,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in DENTSPLY SIRONA by 700.0% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,792 shares of the medical instruments supplier's stock worth $33,000 after buying an additional 1,568 shares in the last quarter. Institutional investors and hedge funds own 95.70% of the company's stock.

About DENTSPLY SIRONA

(Get Free Report)

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.

Recommended Stories

Analyst Recommendations for DENTSPLY SIRONA (NASDAQ:XRAY)

Should You Invest $1,000 in DENTSPLY SIRONA Right Now?

Before you consider DENTSPLY SIRONA, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DENTSPLY SIRONA wasn't on the list.

While DENTSPLY SIRONA currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines